Mercer Global Advisors
ARCT icon

Mercer Global Advisors’s Arcturus Therapeutics ARCT Stock Holding History

Mercer Global Advisors’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$161K Buy
24,006
+13,118
+120% +$103K ﹤0.01% 3318
2026
Q1 		$84.1K Buy
10,888
+381
+4% +$2.78K ﹤0.01% 3057
2025
Q4 		$64.4K Buy
+10,507
New +$113K ﹤0.01% 2769

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Mercer Global Advisors's ARCT Position: Q2 2026 in Review

Mercer Global Advisors increased its Arcturus Therapeutics (ARCT) stake by 120% in Q2 2026, buying an estimated $103K and bringing the position to 24,006 shares worth $161K. The position accounts for ﹤0.01% of the portfolio, ranked #3318.

Mercer Global Advisors first reported a position in ARCT in Q4 2025 and has held it in 3 quarters since. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Mercer Global Advisors held 24,006 shares of Arcturus Therapeutics worth $161K as of Q2 2026.
  • Mercer Global Advisors bought 13,118 Arcturus Therapeutics shares in Q2 2026, an estimated $103K.
  • Arcturus Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #3318 holding.
  • Mercer Global Advisors first reported a position in Arcturus Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.